Very well presented and well written annual report. The Chairman’s address says it all. All value drivers remain the same. I have a feeling this annual report is considerably more a marketing document for the company than ever before. It’s obvious they will be targeting specific instos, and I expect the register will gradually change from retail to institutional over time (over the coming 6 to 12 months). I’m still not sure RE capital raising, but any discount would be minimal and the positive will be full steam ahead for phase 2 in 2591. I hope they announce progress soon on phase 1, even if it is just that they have commenced. I have a strong feeling that if we wind the clock forward 12 months we won’t recognise what we have today. Best of luck all.
- Forums
- ASX - By Stock
- NEU
- Ann: Annual Report 2019
NEU
neuren pharmaceuticals limited
Add to My Watchlist
1.87%
!
$13.09

Ann: Annual Report 2019, page-2
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$13.09 |
Change
0.240(1.87%) |
Mkt cap ! $1.635B |
Open | High | Low | Value | Volume |
$13.15 | $13.37 | $12.92 | $5.015M | 382.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
7 | 286 | $13.08 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.10 | 400 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 335 | 13.080 |
6 | 696 | 13.070 |
9 | 1494 | 13.060 |
8 | 1628 | 13.050 |
5 | 1327 | 13.040 |
Price($) | Vol. | No. |
---|---|---|
13.100 | 400 | 4 |
13.110 | 845 | 6 |
13.120 | 1484 | 6 |
13.130 | 2182 | 11 |
13.140 | 1924 | 13 |
Last trade - 13.36pm 18/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online